Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Taiwan / NCT04592913
Active, not recruiting Phase 3

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913 · tracked via the Priya Life Science Taiwan tracker
Sponsor
AstraZeneca
Phase
Phase 3
Started
2020-11-17
Last updated
2025-12-24

Condition(s) studied

Gastrointestinal NeoplasmsEsophagogastric Junction

Investigational drug(s) / intervention(s)

Durvalumab →FLOT chemotherapy

Durvalumab: Human monoclonal antibody

FLOT chemotherapy: A combination treatment made up of flurouroacil + leucovorin + oxaliplatin + docetaxel

Study summary

This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).

Eligibility

Sex
ALL
Min age
18 Years
Max age
200 Years
Healthy volunteers
No
Key Inclusion Criteria: * Patients with histologically documented gastric or gastroesophageal junction adenocarcinoma with resectable disease (Stage II or higher per AJCC 8th edition). * Patients must undergo radical surgery. * No prior anti-cancer therapy for the current malignancy. * World Health Organization (WHO)/ECOG performance status of 0 or 1 at enrollment. * Adequate organ and marrow function. * Availability of tumor sample prior to study entry. * Must have a life expectancy of at least 24 weeks. Key Exclusion Criteria: * Patients with peritoneal dissemination or distant metastasis. * Patients with adenosquamous cell carcinoma, squamous cell carcinoma, or GI stromal tumor. * Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab. * Contra-indication to any of the study drugs. * History of allogeneic organ transplantation.

Primary outcome measure(s)

  • Event-free survival (EFS) — Up to 5 years
    EFS is the time from date of randomization until the date of disease progression or death.

Trial sites (156)

FacilityCityRegionStatus
Research Site Duarte California
Research Site Los Angeles California
Research Site Los Angeles California
Research Site Sylmar California
Research Site St. Petersburg Florida
Research Site Tallahassee Florida
Research Site West Palm Beach Florida
Research Site Fort Wayne Indiana
Research Site Louisville Kentucky
Research Site Boston Massachusetts
Research Site New York New York
Research Site Rochester New York
Research Site Nashville Tennessee
Research Site Dallas Texas
Research Site Lancaster Texas
Research Site Seattle Washington
Research Site Buenos Aires Argentina
Research Site Ciudad Autonoma Buenos Aires Argentina
Research Site Ciudad de Buenos Aires Argentina
Research Site Ciudad de Buenos Aires Argentina
Research Site Rosario Argentina
Research Site Rosario Argentina
Research Site Charleroi Belgium
Research Site Edegem Belgium
Research Site Leuven Belgium
Research Site Liège Belgium
Research Site Roeselare Belgium
Research Site Barretos Brazil
Research Site Natal Brazil
Research Site Porto Alegre Brazil
Research Site Porto Alegre Brazil
Research Site Rio de Janeiro Brazil
Research Site São José do Rio Preto Brazil
Research Site São Paulo Brazil
Research Site Edmonton Alberta
Research Site North York Ontario
Research Site Oshawa Ontario
Research Site Toronto Ontario
Research Site Montreal Quebec
Research Site Montreal Canada

+ 116 more sites — see the full list on the official registry below.

On this site

📄 Imfinzi (durvalumab) drug profile →

More AstraZeneca trials in Taiwan

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) Active, not recruiting
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer Recruiting
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC Active, not recruiting
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia Recruiting
Volrustomig Priming Regimens Exploratory Phase II Platform Study Active, not recruiting

Other trials for the same condition

Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04592913 on ClinicalTrials.gov ↗ ← All trials in Taiwan